Improved recrystallization processes for obtaining anhydrous optically active lansoprazole
CA 2409044 C · Owner: Maruyama, Hideaki · Inventors: Maruyama, Hideaki; Hashimoto, Hideo
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a production method of a crystal of (R)-2-3-methyl-4-(2,2,2-trifluoroethoxy)-2pyridylmethylsulfinylbenzimidazole . n'H2O (wherein n' is about 0 to about 0.1) or a salt thereof which , characteristically includes crystallization from an organic solvent solution or suspension in which (R)-2-3-methyl-4- (2,2,2-trifluoroethoxy)-2-pyridylmethylsulfinylbenzimidazole . nH2O (wherein n is about 0.1 to about 1.0) or a salt thereof has been dissolved or suspended and the like, and , provides a convenient method for efficiently producing an optically active sulfoxide derivative having an extremely high enantiomer excess in high yield at an industrial large scale.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 15, 2001 and granted February 19, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 15, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 15, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.